Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 16, 2024 05:30 ET | Source: Neurogastrx

Neurogastrx Announces Positive Proof-of-Concept Data for Investigational Drug NG101 in Reducing Nausea and Vomiting Associated with the Administration of GLP-1 Agonist Medication

Neurogastrx Announces Positive POC Data for Investigational Drug NG101 in Reducing Nausea & Vomiting Associated with GLP-1 Agonists
June 07, 2024 09:26 ET | Source: Research and Markets

Opioid-Induced Constipation Market Trends, Epidemiology, and Unmet Needs to 2034: 7MM Projected to Reach $1.16 Billion

Dublin, June 07, 2024 (GLOBE NEWSWIRE) -- The "Opioid-Induced Constipation Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034" report has been added to ...
October 10, 2023 07:18 ET | Source: Research and Markets

Viral Gastroenteritis Global Market Report 2023: A $7.68 Billion Market by 2027 - Product Innovation and FDA Approvals Fuel Growth to 2032

Dublin, Oct. 10, 2023 (GLOBE NEWSWIRE) -- The "Viral Gastroenteritis Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.The global viral gastroenteritis market is...
November 03, 2015 11:50 ET | Source: Neurogastrx

Neurogastrx Appoints Baxter Phillips III as President and Chief Executive Officer

CAMPBELL, Calif., Nov. 03, 2015 (GLOBE NEWSWIRE) -- Neurogastrx, a biopharmaceutical company engaged in developing novel drugs for gastrointestinal disorders, today announced the appointment of...